Management issues in the metabolic syndrome

Area of Science:

• Cardiology
• Endocrinology
• Metabolic Disorders

Background:

• Metabolic syndrome is a cluster of conditions including obesity, insulin resistance, dyslipidemia, and hypertension.
• Physical inactivity and poor diet are major risk factors, with central obesity being a key feature.
• India has a high prevalence of type-2 diabetes, suggesting a large burden of metabolic syndrome.

Purpose of the Study:

• To review the characteristics and therapeutic approaches for metabolic syndrome.
• To highlight the role of pharmacotherapy when lifestyle modifications are insufficient.
• To discuss emerging drug classes and treatment strategies.

Main Methods:

• Review of epidemiological data and therapeutic strategies for metabolic syndrome.
• Discussion of pharmacological agents for obesity, dyslipidemia, insulin resistance, and hypertension.
• Exploration of novel drug classes and combination therapies.

Main Results:

• Metabolic syndrome presents with elevated triglycerides, low HDL, high LDL, hypertension, and hyperglycemia.
• Pharmacological treatments include anti-obesity agents (sibutramine, orlistat), statins, fibrates, nicotinic acid, ezetimibe, thiazolidinediones, and ACE inhibitors/ARBs.
• Emerging therapies like PPAR agonists and cannabinoid receptor-1 antagonists show potential.

Conclusions:

• Management of metabolic syndrome requires a multifactorial approach addressing individual risk factors.
• Pharmacotherapy is crucial when lifestyle changes fail, with various drug classes available.
• Novel drug developments and fixed-dose combination therapies may offer future treatment advancements.